Debating who should get pricey hep C drugs is close to asking, ‘What’s the value of a life?’
Simple math illustrates the challenge facing U.S. taxpayers, consumers and insurers following the launch late last year of two expensive new drugs to treat hepatitis C. If all 3 million people estimated to be infected with the virus in America...